233 related articles for article (PubMed ID: 37949318)
1. Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit.
Hsieh HC; Chen CC; Chou PH; Liu WC; Wu SC
Antiviral Res; 2023 Dec; 220():105752. PubMed ID: 37949318
[TBL] [Abstract][Full Text] [Related]
2. Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice.
Cai JP; Luo C; Wang K; Cao H; Chen LL; Zhang X; Han Y; Yin F; Zhang AJ; Chu H; Yuan S; Kok KH; To KK; Chen H; Chen Z; Jin DY; Yuen KY; Chan JF
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992395
[TBL] [Abstract][Full Text] [Related]
3. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
4. Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.
Pitcovski J; Gruzdev N; Abzach A; Katz C; Ben-Adiva R; Brand-Shwartz M; Yadid I; Ratzon-Ashkenazi E; Emquies K; Israeli H; Haviv H; Rapoport I; Bloch I; Shadmon R; Eitan Z; Eliahu D; Hilel T; Laster M; Kremer-Tal S; Byk-Tennenbaum T; Shahar E
Vaccine; 2022 Feb; 40(8):1098-1107. PubMed ID: 35078662
[TBL] [Abstract][Full Text] [Related]
5. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
Freitag TL; Fagerlund R; Karam NL; Leppänen VM; Ugurlu H; Kant R; Mäkinen P; Tawfek A; Jha SK; Strandin T; Leskinen K; Hepojoki J; Kesti T; Kareinen L; Kuivanen S; Koivulehto E; Sormunen A; Laidinen S; Khattab A; Saavalainen P; Meri S; Kipar A; Sironen T; Vapalahti O; Alitalo K; Ylä-Herttuala S; Saksela K
Vaccine; 2023 May; 41(20):3233-3246. PubMed ID: 37085458
[TBL] [Abstract][Full Text] [Related]
6. Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.
Wang Q; Yang C; Yin L; Sun J; Wang W; Li H; Zhang Z; Chen S; Liu B; Liu Z; Shi L; Liu X; Guan S; Wang C; Qu L; Feng Y; Niu X; Feng L; Zhao J; Li P; Chen L; Zhong N
Signal Transduct Target Ther; 2023 Apr; 8(1):167. PubMed ID: 37069171
[TBL] [Abstract][Full Text] [Related]
7. Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
Lee KS; Rader NA; Miller-Stump OA; Cooper M; Wong TY; Shahrier Amin M; Barbier M; Bevere JR; Ernst RK; Heath Damron F
Vaccine; 2023 Jul; 41(34):5003-5017. PubMed ID: 37407405
[TBL] [Abstract][Full Text] [Related]
8. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
Front Immunol; 2022; 13():908478. PubMed ID: 35844601
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
Ji Y; Sui X; Miao W; Wang C; Wang Q; Duan Z; Wei B; Wu D; Wei M; Shao J; Zheng X; Zhu T
Vaccine; 2024 Feb; 42(6):1292-1299. PubMed ID: 38296705
[TBL] [Abstract][Full Text] [Related]
12. Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development.
Jearanaiwitayakul T; Sunintaboon P; Kittiayuwat A; Limthongkul J; Wathanaphol J; Janhirun Y; Lerdsamran H; Wiriyarat W; Ubol S
Vaccine; 2024 Jun; 42(17):3664-3673. PubMed ID: 38714446
[TBL] [Abstract][Full Text] [Related]
13. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
Kim E; Khan MS; Ferrari A; Huang S; Sammartino JC; Percivalle E; Kenniston TW; Cassaniti I; Baldanti F; Gambotto A
Microbiol Spectr; 2023 Jun; 11(3):e0436322. PubMed ID: 37162333
[TBL] [Abstract][Full Text] [Related]
15. Mucosal IgA response elicited by intranasal immunization of Lactobacillus plantarum expressing surface-displayed RBD protein of SARS-CoV-2.
Li L; Wang M; Hao J; Han J; Fu T; Bai J; Tian M; Jin N; Zhu G; Li C
Int J Biol Macromol; 2021 Nov; 190():409-416. PubMed ID: 34499954
[TBL] [Abstract][Full Text] [Related]
16. Intranasal administration of unadjuvanted SARS-CoV-2 spike antigen boosts antigen-specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters.
Agbayani G; Akache B; Renner TM; Tran A; Stuible M; Dudani R; Harrison BA; Duque D; Bavananthasivam J; Deschatelets L; Hemraz UD; Régnier S; Durocher Y; McCluskie MJ
Eur J Immunol; 2024 Jun; 54(6):e2350620. PubMed ID: 38561974
[TBL] [Abstract][Full Text] [Related]
17. Intranasal immunization with recombinant Vaccinia virus encoding trimeric SARS-CoV-2 spike receptor-binding domain induces neutralizing antibody.
Cao X; Zai J; Zhao Q; Xie L; Li Y
Vaccine; 2022 Sep; 40(40):5757-5763. PubMed ID: 36055873
[TBL] [Abstract][Full Text] [Related]
18. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
19. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
[TBL] [Abstract][Full Text] [Related]
20. Humoral immune response to authentic circulating severe acute respiratory syndrome coronavirus 2 variants elicited by booster vaccination with distinct receptor-binding domain subunits in mice.
Jiang Y; Zhang H; Yu J; Huang D; Zhai L; Li M; Wang Y; Ren Z; Zou L; Zheng Z; Hu H; Zhang J; Zhang B; Zhao W; Yang X; Li B; Shen C
J Med Virol; 2022 Sep; 94(9):4533-4538. PubMed ID: 35614018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
